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1. Introduction
Our bodies are able and required to modify proteins post-
translationally with a wealth of moieties both site-selectively
and site-specifically for a myriad of essential processes includ-
ing cell growth, repair and death. The ability to mimic these
processes &&outside of an in vivo environment “ex vivo”?&
& allows researchers to &&recapitulate “mimic”?&& nature,
to explore biosynthetic pathways, to manipulate and to deci-
pher natural protein function, and to attach affinity or fluores-
cent tags for imaging. Chemical protein modification contrib-
utes to the enhancement of therapeutic properties,[1, 2] as well
as in diagnostic applications in, for example, surface immobili-
sation for biosensor design.[3] It is important not to underesti-
mate the potential involved in the marrying of two or more
bio-macromolecular and/or small-molecule functionalities to
form structurally and functionally diverse bioconjugates.
Proteins, as an example of a class of bio-macromolecules,
are robust and powerful entities; however, their structure and
function can be sensitive to general conditions employed in
conventional organic syntheses. These include raised tempera-
tures and the use of organic solvent, two factors likely to per-
turb protein structure. As well as ambient reaction conditions,
high conversion rates and minimal generation of side products
are desired, in order to avoid tedious purification steps. Modifi-
cation at a single site is therefore generally preferred, to avoid
heterogeneity.
Existing methods for chemical protein modification include
the use of naturally occurring amino acids such as lysine,
serine, histidine and tyrosine,[4–6] and also of unnatural amino
acids (UAAs), incorporated by use of genetically engineered
bacterial strains[7,8] and/or enzymatic methods.[9] These meth-
ods although useful, do have drawbacks.
The use of naturally occurring amino acids does allow the
avoidance of demanding genetic engineering. Although lysine
modification is commonly used and facile, the residue’s high
level of occurrence in proteins means that multiple sites can
be modified in an unpredictable manner. This leads to hetero-
geneity and/or the blocking of functional sites by the newly in-
troduced group. Site-specificity during endogenous amino acid
modification can be promoted by exploiting the differential re-
activity of the N terminus, for example,[10] or by the use of
enzyme recognition sequences.[11] Overall, however, the use of
most endogenous amino acids for modification purposes is dif-
ficult to apply in a general manner due to higher levels of oc-
currence, leading to modification of multiple sites.
A wealth of UAAs can be incorporated into proteins by use
of the amber suppression methods pioneered by Schultz and
Chin.[7,12,13] Such UAAs include photocaged cysteine resi-
dues.[14,15] The methodology, based on incorporating orthogo-
nally reactive functionalities, is very elegant and a sure-fire way
to ensure reactivity at a single site. Yet it can be more time-
consuming than the use of endogenous amino acids. Alterna-
tively, unnatural tags can be incorporated through chemoenzy-
matic methods.[9] Here, site-specific reactivity is guaranteed,
but the use of enzymes is more resource-dependent.
It can be argued that modification through cysteine residues
combines the advantages of the approaches described above.
The presence of multiple accessible free cysteine residues
within a protein is likely to result in multi-site modification, but
cysteine has a low natural abundance, which means that selec-
tivity on a general level is more likely. In addition, cysteine resi-
dues can be readily introduced by use of facile mutagenesis
techniques prior to expression, allowing control over the site
of modification. The ease of incorporation and associated ex-
pression yields are specifically dependent on the protein’s
structure and behaviour. Another characteristic of cysteine is
that it has a unique nucleophilicity, in comparison with other
reactive side chains. Under physiological conditions, it has
a high propensity to form the nucleophilic thiolate ion with
a general pKa of 8.2. This, though, is highly dependent on its
conformation and its environment in terms of buffer and
neighbouring residues, and can be even lower.[16,17] As well as
a unique reactivity, cysteine also has an incredibly diverse reac-
tivity profile, as exemplified by the abundance of post-transla-
tional modifications (PTMs) it undergoes.[18] It is able to inter-
convert between multiple oxidation states, often negates the
need for co-factors in vivo, and is essential in cellular redox
regulation. Cysteine is able to partake in exchange, radical and
atom-, electron- and hydride-transfer reactions, and also to
bind to metals.[19] Its evolutionary diversity undoubtedly pro-
vides inspiration for the protein chemist developing cysteine-
based methodology at the bench.
This review focuses on methodologies involving cysteine as
a precursor for chemical modification of proteins since 2009,
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The modification of proteins with non-protein entities is impor-
tant for a wealth of applications, and methods for chemically
modifying proteins attract considerable attention. Generally,
modification is desired at a single site to maintain homogenei-
ty and to minimise loss of function. Though protein modifica-
tion can be achieved by targeting some natural amino acid
side chains, this often leads to ill-defined and randomly modi-
fied proteins. Amongst the natural amino acids, cysteine com-
bines advantageous properties contributing to its suitability
for site-selective modification, including a unique nucleophilici-
ty, and a low natural abundance—both allowing chemo- and
regioselectivity. Native cysteine residues can be targeted, or
Cys can be introduced at a desired site in a protein by means
of reliable genetic engineering techniques. This review on
chemical protein modification through cysteine should appeal
to those interested in modifying proteins for a range of appli-
cations.
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when Chalker et al. reviewed the same topic.[20] Since then,
there has been exponential growth both in new cysteine-
based chemistries and in more applied reports based on exist-
ing cysteine methodologies. Native chemical ligation (NCL)[21] is
not discussed in great detail, but has been reviewed else-
where.[22,23] Although NCL is an elegant method for the total
synthesis of proteins (ligating peptide fragments together) and
has seen many applications, our interests lie in conjugating
non-protein moieties to proteins through cysteine residues.
We have opted for a systematic review of new developments,
classified according to the specific sulfur-based chemistry used.
2. Modification by Substitution
2.1. Alkylation through SN2 reaction with haloalkyl reagents
One of the earliest methods used for modifying cysteine resi-
dues within proteins is by substitution with haloalkyl sub-
strates bearing groups of interest. Iodide and bromide groups
in particular are commonly used.[20] Indeed, substitution with
iodoacetamide is routinely used to “cap” cysteine residues in
protein digestion prior to analysis. Drawbacks associated with
haloalkyl substitution are potential crossreactivity with other
nucleophilic side chains such as lysine and histidine, and sus-
ceptibility of reagents to hydrolysis ; hence the need to devel-
op alternative methodologies as outlined in the remainder of
this review. However, despite these drawbacks, there are many
examples of the use of haloalkyl substituents in alkylating or
arylating cysteine residues within proteins over the last few
years (Scheme 1). In many cases the common ease and reliabil-
ity of these reactions means that the need for modification op-
timisation is potentially minimised, and an application can be
realised in a quicker timeframe. One example is the incorpora-
tion of the nitrile group into proteins by using benzyl com-
pounds with either bromo or nitrile substituents for the devel-
opment of infrared probes.[24]
Chalker et al. used cysteine as one component of a precursor
incorporating a thioether-linked para-iodophenyl moiety as
a coupling partner for Suzuki–Miyaura coupling,[25] whereas
Mayer et al. modified the Grubbs catalyst with a bromoaceta-
mide group for conjugation to a protein to form a metalloen-
zyme capable of catalysing a ring-closing metathesis, although
further optimisation is required.[26]
The use of folic acid as a targeting moiety in therapeutics is
widely known,[27] and a folic acid derivative bearing a bromoalk-
yl group was conjugated to an engineered cysteine residue in
RNase A, leading to a homogenous conjugate capable of tar-
geting cancerous cells without loss of activity.[28] Substitution
in this way can also be used as a method for forming homoge-
nous glycoproteins.[29–31]
“Stapling” of residues within peptide chains is known to
induce secondary structure, aiding the interaction ability of the
peptide with, for instance, protein binding pockets or DNA. So
called peptide stapling can be carried out on two proximal cys-
teine residues with a structurally rigid &&di-bromoalkyl “di-
bromoalkyl”? “bis(bromoalkyl)”?&& linker for protein–protein
interaction (PPI) mimicry.[32–34] Stapling can also be applied to
proteins, as reported recently with the use of tetrazines bear-
ing chloride groups for cysteine conjugation (Scheme 2). A
novel feature of this method is that, post-stapling, further func-
tionalisation can be carried out through inverse-electron-
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Scheme 1. Examples of reagents used for protein modification through nu-
cleophilic substitution on Cys.
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demand Diels–Alder cycloaddition with a strained cyclooctyne,
as demonstrated on thioredoxin protein (Scheme 2). Alterna-
tively, unstapling can be performed photochemically, although
this is not the most generally applicable method.[35] Alkylation
of maltose-binding protein (MBP) with a &&chloroacetamide-
appended OK?&& fluorophore was achieved by Sunbul et al. ,
followed by proximity-induced binding to a fused fluorophore-
binding peptide. The methodology was found to achieve se-
lective labelling of bacterial cells overexpressing the MBP-fluo-
rophore binding peptide fusion.[36]
Hamamoto et al. reported a method for spontaneous yet
controlled cyclisation, in which an unnatural amino acid bear-
ing a haloalkyl moiety, as well as a suitably positioned cysteine
residue, is genetically incorporated into a protein. Hence, post-
expression, cyclisation occurs through reaction between the
two appropriately placed amino acids.[37]
An impressive display of cysteine’s ability to react not only
selectively, but also in a plethora of different ways, is shown in
the synthesis of diubiquitin probes. Two ubiquitin moieties
were conjugated through haloalkyl substitution, through
which a Michael addition acceptor (in this case an a,b-unsatu-
rated moiety) was &&attached for probing purposes to the
active-site cysteine residue in deubiquitinases OK?&&.[38] DAR-
Pins (designed ankyrin repeat proteins) can be dually modified
at carefully positioned cysteine residues, as shown by Moody
et al. , who functionalised these binding proteins by sequential
substitution and maleimide coupling.[39]
An example of cysteine alkylation through non-halogen-
mediated nucleophilic substitution is the ring opening of aziri-
dines, such as methylthiocarbonyl-aziridine. A series of histone
PTM mimics were synthesised and found to be recognised by
antibodies raised against the naturally occurring PTMs.[40]
2.2. Perfluoroarylation
Pentelute’s laboratory reported nucleophilic aromatic substitu-
tion (SNAr) between cysteine residues in peptides and proteins
and perfluoroaromatic molecules (Scheme 3). They stapled
a range of peptides, each bearing two cysteine residues, &
&inferring “conferring”?&& increased structural stability, as
well as a trihelical affibody.[41] This led to enhanced binding
ability, cell permeability and overall stability.[42] Although
a clear application was achieved in terms of enhancement of
the affibody’s properties, yields were low, due to poor solubili-
ty and reactivity of the perfluoroaromatic reagents. As an alter-
native, glutathione transferase (GST) was used for catalysing
the reaction with a protein containing an N-terminal gluta-
thione motif, allowing site-selectivity in the presence of other
cysteine residues.[43] Although some genetic engineering is re-
quired for applying the procedure on proteins, the reaction is
complete within a matter of seconds. The methodology has
also been applied extensively to peptidic systems, particularly
in the context of performing macrocyclisations rapidly.[44,45]
3. Maleimides
3.1. &&C-Unsubstituted&& maleimides
Maleimides are Michael acceptors, and reaction between a mal-
eimide and a cysteine thiolate forms a thiosuccinimide bond
(Scheme 4). The first conjugation reaction between a maleimide
and a cysteine residue within a protein was described by
Moore and Ward; bis-maleimides were used to cross-link cys-
teine-containing proteins.[46] Tsao and Bailey also carried out
maleimide–thiol coupling in a method for the extraction and
Scheme 2. Peptide stapling by use of tetrazine chloride reagents, together
with functionalisation of thioredoxin with a fluorophore post stapling. Thio-
redoxin (PDB ID: 1XOB).
Scheme 3. SNAr reactions between perfluoroaromatic molecules and cys-
teine residues in peptides and proteins.
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purification of actin and subsequent identification of sulfhydryl
content by treatment with N-ethylmaleimide (NEM, titration of
protein with NEM displacing sodium nitroprusside).[47] They
were inspired by Friedmann’s investigations into the antimitot-
ic activity of maleimide compounds, which involved treatment
of maleimides with glutathione (GSH).[48] The impact that male-
imide–thiol coupling would have in the future was understand-
ably not fully appreciated or recognised at this point. Over the
next few years after their initial applications, maleimide re-
agents were developed as blocking reagents for sulfhydryl
groups within proteins for analytical purposes, for mapping
cysteine residues in proteins with the aid of fluorescent malei-
mides[49,50] and, years later, for modification of proteins with
maleimides for various applications. Maleimide–thiol conjuga-
tion became well-established, and therefore more application-
based papers appeared, despite degradation worries that are
discussed below.
To date, maleimide–thiol coupling still remains the biochem-
ist’s preferred method for the scalable chemical modification
of proteins through cysteine residues. The reliability of malei-
mide–thiol conjugation means it can be used as a handle for
multi-step functionalisations, to introduce, for example, an
alkene functionality, which is then subjected to further reac-
tion.[51] Antibody-containing therapeutics based on conjugates
formed by maleimide–thiol coupling are already on the
market, exemplifying the applicability of this chemistry, and
further research is ongoing.[52] Cimzia, a PEGylated anti-TNF
construct developed by UCB, for example, is FDA-approved for
the treatment of&&Crohn’s OK?&& disease and rheumatoid
arthritis.[53] Antibody–drug conjugates (ADCs) comprise an area
of research worth billions of dollars, utilising the cytotoxic
effect of small-molecule drugs and the unmatched specificity
of antibodies, resulting in targeted therapies.[1,2] Brentuximab
vedotin—consisting of an anti-CD30 antibody conjugated to
monomethyl aurostatin E (MMAE) through a protease-cleava-
ble linker—is the first ADC to be approved for the treatment
of Hodgkin’s lymphoma and systemic &&anaplastic large cell
lymphoma (ALCL OK?&&, Scheme 5).[55] MMAE is too cytotox-
ic to be administered alone; hence the importance of conjuga-
tion to the antibody. In order for drugs to maintain their cyto-
toxic effects when conjugated to antibodies, more than one
drug molecule usually needs to be attached to a single anti-
body (efficient drug/antibody ratio, DAR). In this respect, multi-
ple sites need to be modified but residue specificity is necessa-
ry. This can be achieved by the incorporation of cysteine resi-
dues for modification at predicted sites, where they will not
perturb antibody function or disrupt folding. This approach
(coined THIOMAB technology), developed by researchers at
Genentech, can be advantageous over the use of native lysine
residues, for which DAR is less predictable.[52,56]
The use of maleimides in chemical protein modification is
advantageous for a number of reasons, including their high se-
lectivity towards thiol groups to form succinimide thioethers,
a lack of side products, and the ability to carry out transforma-
tions in aqueous media in the absence of catalysts, often with-
out any heating. In addition, the maleimide moiety can be
functionalised through the nitrogen atom in the ring with
a wide range of conjugation partners such as fluorophores,
polymer moieties and lipids. The maleimide moiety can be in-
troduced into a target compound for conjugation by use of
straightforward chemistry, such as by the addition of maleic
anhydride to amines, and many maleimide compounds are
now commercially available. Thiosuccinimide bond formation
was previously considered to be irreversible; however, observa-
tions that retro-Michael addition takes place as well as hydroly-
sis of the ring have led to uncertainties and further explora-
tions into the integrity of the bond. This is discussed after
a brief overview of recent applications of maleimide use in
chemical protein modification through cysteine.
3.1.1. Recent examples of cysteine modification involving mal-
eimide chemistry : In 2008, Dumelin et al. discovered a series of
low-molecular-weight noncovalent albumin-binding entities
based on the lead structure 4-(p-iodophenyl)butyric acid, iden-
tified from a DNA-encoded chemical library.[57] A maleimide-
containing version of the parent compound—(2-(3-maleimido-
propanamido-)-6(4-(4-iodophenyl)butanamido hexanoate)—
Scheme 4. Cysteine-mediated protein modification with maleimide reagents.
Scheme 5. The structure of the ADC Brentuximab vedotin.
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was then synthesised in a small number of steps by simple N’-
(3-dimethylaminopropyl)-N-ethylcarbodiimide/N-hydroxysucci-
nimide (EDC/NHS) coupling chemistry, and then conjugated to
an antibody fragment specific for a tumour-associated antigen
and containing a C-terminal cysteine residue. A dramatic in-
crease in tumour uptake in rodents was observed; this demon-
strated that success had been achieved in increasing the half-
life of the antibody in vivo through binding to albumin, and
also that the conjugate formed was sufficiently stable in blood
plasma.[58] The simple yet effective strategy has the potential
to be quite general. Simon et al. coupled two biorthogonal
chemistries (one of them maleimide–cysteine thiol coupling)
to assemble stable DARPin conjugates each bearing a cytotoxic
drug, as well as albumin, for half-life extension.[59]
For Cheng et al. , the thiosuccinimide bond again proved
stable in another in vivo application, in which conjugation of
an affibody to a maleimide-functionalised chelator allowed ra-
diolabelling with 64Cu and subsequent positron emission to-
mography (PET) imaging in mice, to establish biodistribution
patterns.[60] Tavare et al. reported a slightly different method
for radiolabelling, in which a C-terminal sequence consisting of
a cysteine, spacer and hexahistidine motif was engineered into
a phosphatidyl-binding domain of rat synaptotatgmin I; this
might be useful for mapping apoptosis through the resulting
exposure of phosphatidyl serine on apoptotic cell surfaces. The
hexahistidine tag was used for the attachment of
[99mTc(CO)3(OH2)3]
+ , whereas fluorescein-maleimide was con-
jugated to the free cysteine for imaging purposes.[61]
Protein-based artificial metalloenzymes might help in &
&inferring “achieving”?&& enantioselectivity ; their develop-
ment involves introducing synthetic catalytic moieties into pro-
teins.[62,63] Laan et al. successfully synthesised a ruthenium
complex containing a maleimide unit and were able to couple
it to photoactive yellow protein (PYP).[64] Its catalytic activity is
yet to be tested, and might be affected by a need for organic
co-solvents, likely to cause protein denaturation, as well as by
a potential need for high pressures and temperatures and long
reaction times.
Site-selective glycosylation of bovine haemoglobin was dem-
onstrated by Zhang et al. , who conjugated a maleimide-deriva-
tised lactose unit onto a free cysteine residue. It was demon-
strated that the glycoconjugate had a high affinity for
oxygen.[65] A conjugate of this sort might help with stabilisa-
tion of the protein in vivo, and hence in the development of
a strategy for oxygen delivery after haemorrhagic shock.
A very recent example of the use of unsubstituted malei-
mides has been described by Haralampiev et al. They incorpo-
rated a palmitic acid moiety functionalised with a maleimide
unit into model unilamellar vesicle systems, as well as into
a biological membrane (on macrophages); this could be fur-
ther used to recruit a cysteine-containing rhodamine-labelled
peptide for potential detection and monitoring of certain
membrane processes (Scheme 6).[66] However, cell-surface
thiols (exofacial thiols) have been proposed as a potential re-
cruitment strategy for drugs, and so crossreactivity is possible.
Recent work by Li and Takeoka has exploited these thiols,
using liposomes incorporating maleimide moieties for specific
targeting of exofacial thiols. Enhanced uptake of these lipo-
somes (encapsulating doxorubicin) was observed both in vitro
and in vivo. The reactions between thiols and maleimides are
remarkably selective, as demonstrated in this case, in which
the reactive groups are not only surrounded by other protei-
nogenic functionalities, but also by the plethora of chemical
groups present on a cell surface.[67,68]
Egenberger et al. carried out multiple glycine-to-cysteine
mutations within the substrate-binding domain of OCT1 (or-
ganic cation transporter 1). Facile fluorescence labelling with
the bulky tetramethylrhodamine-6-maleimide led to substrate
blocking, identified by fluorescence measurements, and the
importance of this position could be elucidated as a result.[69]
The generality of maleimide–thiol coupling is demonstrated by
the fact that many maleimide-derivatised fluorophores are
commercially available (as well as other maleimide-containing
compounds), which promotes their use in a routine manner,
especially by non-chemists. Fluorescent probes have been
used in investigating protein folding mechanisms and path-
ways,[70,71] as well as for characterisation and mapping of cys-
teine residues in antibody variants.[72] Song et al. reported the
synthesis of a small-molecule fluorescent probe containing
a coumarin and maleimide unit, which was used for antibody
labelling.[73]
SMCC [succinimidyl trans-4-(maleimidylmethyl)cyclohexane-
1-carboxylate] , a heterobifunctional linker containing a malei-
mide and an NHS ester unit] was recently used to conjugate
a polyhistidine peptide to DNA capable of cross-linking to cis-
platin in order to perform “pull-down” experiments to identify
modification states of proteins binding to cisplatin.[74] Malei-
mides have also been used to investigate the role of cysteine
oxidation in cell signalling,[75] for elucidating roles of endoge-
nous cysteine residues in various protein systems,[76,77] and for
Scheme 6. Recruitment of maleimide-functionalised lipids to biological membranes.
ChemBioChem 2016, 17, 2 – 27 www.chembiochem.org  2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim7
These are not the final page numbers! 
Reviews
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
identifying and isolating epidermal growth factor receptor
(EGFR)-binding peptides generated by phage display.[78]
Maleimide–thiol coupling has also been used extensively for
the conjugation of biomolecules (proteins and peptides) to
polymers[79] in, for example, the synthesis of nanoparticle drug-
delivery systems,[80] conjugates able to cross the blood–brain
barrier,[81] self-assembling fibril systems,[82] antibody–polymer
conjugates[83] and multimeric polymer–protein conjugates.[84]
De et al. reported a synthesis of a temperature-responsive
polymer–protein conjugate in which polymerisation is carried
out after conjugation of BSA to an initiating group.[85]
Hydrogels have many uses, including as scaffolds in tissue
engineering and as controlled-release drug-delivery systems.[86]
Ito et al. used maleimide-terminated four-armed PEG derivative
for covalent attachment to a peptide capable of binding to
the PDZ domain (a common structural domain in signalling
proteins). This domain in turn mediated certain protein–pro-
tein interactions, which drove hydrogel self-assembly.[87] More
recently, Wang et al. used the same PEG scaffold, but hydrogel
formation was driven by reaction with accessible cysteine resi-
dues on a ubiquitin-like domain (ULD) tetramer.[88] A method
for improved ultrasound targeted imaging based on conjuga-
tion between lipid-based maleimide-containing “bubbles” and
cysteine residues on gelatine might lead to improved detec-
tion and monitoring of thrombus, inflammation and tumour
angiogenesis, among other illnesses.[89]
Finally, the maleimide–thiol methodology has been used in
protein immobilisation techniques: in, for instance, the immo-
bilisation of RGD-containing peptides[90] onto a maleimide-
functionalised poly-p-xylylene coating[91] and the capture of
anti-EGFR antibodies to quantum dots coated with prote-
in G.[92]
The above examples by no means constitute an exhaustive
list of maleimide–cysteine coupling over the last few years, but
they do demonstrate the high potential maleimide chemistry
offers many research groups, leading to a broad spectrum of
applications.
3.1.2. Concerns over the integrity of the thiosuccinimide bond :
The integrity of the thiosuccinimide bond has been the subject
of many recent studies, especially in a therapeutic context. De-
pending on the application, the stability of this bond is
a rather subjective topic because in some cases a cleavable
linker is desirable—with, for example, the release of a drug
forming part of an antibody–drug conjugate (ADC) at the site
of action—but not in others, such as when a bioconjugate is
synthesised for in vivo tracking or imaging.[93]
In 1998, Lewis et al. observed that bis-maleimide-linked radi-
ometal immunoconjugates were unstable in serum, detecting
radiometal–albumin conjugates, indicative of free maleimide
being present and reactive.[94] Ten years later, a team from Se-
attle Genetics also observed conjugation between their malei-
mide-derivatised drug and albumin in plasma.[95] Replacing the
maleimidocaproyl conjugation partner with a bromoacetamide-
caproyl &&variant OK?&& led to overall higher intratumou-
ral drug exposure and a slight increase in in vivo stability.
In general, succinimide thioethers are considered to be
stable, but remain sensitive in reducing environments under
near-physiological conditions. Retro-Michael addition
(Scheme 7) leads to free maleimide in solution and hence to
the potential formation of albumin conjugates. Thiol exchange
can also occur with glutathione, present in blood plasma
(Scheme 7). The equilibrium between maleimide–thiol coupling
and retroaddition generally favours thiosuccinimide bond for-
mation, but this can be dependent on the acidity of the pro-
tons adjacent to the carbonyl groups in the ring. In addition,
the rate and extent of thiol exchange can be modulated by
modifying the Michael donor’s reactivity.[96] Substituents on the
ring can affect the pKa values of protons adjacent to the car-
bonyl groups, which has led to the development of next-gen-
eration maleimides, with tuneable bond-forming properties
(discussed in Section 3.2).
Another side reaction that is known to occur is hydrolysis
and subsequent ring opening (Scheme 7). This does not neces-
sarily represent a problem, because it leads to a stable prod-
uct, insusceptible to thiol exchange. Therefore, promoting hy-
drolysis of maleimide–thiol adducts is popular at the moment,
in particular in the field of ADCs.[97] In contrast, thiosuccinimide
bond breaking is undesirable because it can lead to off-target
Scheme 7. Ring opening of maleimide–thiol conjugates and thiol-exchange routes with GSH. Ab=antibody.
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cytotoxic effects, due to thiol exchange resulting in the free
drug entering the circulation. The exact location of the cys-
teine moiety is important, because differences in solvent acces-
sibility and local charge might affect rates of potential thiol ex-
change and/or retro-Michael reaction. Shen et al. found that
for ADCs, a partially accessible site with a positive local charge
promoted post-conjugation hydrolysis between antibody and
drug, and this method should be generally applicable to other
systems.[98]
Alternatively, inductive effects due to electron-withdrawing
substituents on nitrogen can accelerate ring opening rates,[99]
as can an ethylene glycol spacer, a hexamer form of which was
found to enhance hydrolysis over time in neutral buffer.[100] It
was hypothesised that this proceeded with the aid of a water
molecule coordinated to a proximal PEG oxygen atom, with
correct geometry for subsequent attack on the carbonyl group
of the ring to occur. Lyon et al. developed a self-hydrolysing
conjugate, incorporating a basic amino group adjacent to the
maleimide unit such that, after conjugation to the thiolate-con-
taining antibody, the basic amino group can catalyse ring hy-
drolysis under physiological conditions.[101]
3.2. &&C-Substituted&& maleimides
In 2009, the groups of Baker and Caddick presented next-gen-
eration maleimides (NGMs), demonstrating their bio-orthogon-
ality and reactivity towards cysteine on an amino acid, peptide
and protein level (Scheme 8).[102, 103] At a minimum, experiments
at an amino acid level reveal whether reactivity is possible, re-
action behaviour with peptides reveals chemoselectivity, and
reaction behaviour at a protein level tells whether or not the
conjugation conditions required are compatible with the terti-
ary structure of the protein.
Since then, much work on both applications and exploration
of NGMs has been published. An NGM contains one or two
leaving groups &&adjacent “attached”?&& to the double
bond of the maleimide, and coupling to a thiolate therefore
occurs by way of an addition elimination sequence to form
a thiomaleimide bond (Scheme 8). This is in contrast to the sa-
turated succinimide that forms in the absence of a leaving
group. When two leaving groups (a C-&&disubstituted malei-
mide) are present, the protein can be further functionalised by
addition of another thiol.[103, 104] The range of applications dem-
onstrated over the last few years is quite extraordinary, and in-
cludes disulfide bridging for protein stabilisation, reversible ad-
dition for drug delivery systems and fluorescence tagging.
Moreover, a single NGM can be synthesised to effect a combi-
nation of these applications.
NGM syntheses appear to be straightforward and non-prob-
lematic.[105] In the majority of cases, a little over 1 equiv of re-
agent is required, along with mild conditions compatible with
protein environments and short reaction times for protein
modification to occur. The thiomaleimide conjugate resulting
from reaction with a bromomaleimide is reversibly reactive,
and can be cleaved with tris(2-carboxyethyl)phosphine (TCEP;
1 equiv) or a large excess of thiol without any racemisation at
the cysteine residue.[102,103] Cleavage was also observed under
simulated intracellular cytoplasmic conditions, and then under
actual cellular conditions by incubation of rhodamine–green
fluorescent protein conjugates in human cells and testing for
cleavage by monitoring differences in fluorescence resonance
energy transfer (FRET) intensities.[106] This intracellular cleavage
is likely due to an elevated level of GSH in cells relative to
plasma, thus implying that the methodology could be useful
in a drug-release strategy.[107]
3.2.1. Structural features of substituted&&C-substituted&&
maleimides and demonstrated applications : Halogen leaving
groups were compared for reactivities, and it was found that
the rate-determining step for conjugation was likely to be in-
fluenced by leaving group ability, because the iodide group re-
acted more rapidly than bromide and chloride groups.[108]
&&Dithiophenylmaleimide “Bis(thiophenyl)maleimide”?&&
was also found to be very reactive with cysteine residues in
proteins, and was applied in disulfide bridging applications. Di-
sulfide bridging involves the replacement of native disulfide
bonds with structural mimics, with the aim of mimicking the
disulfide’s ability to stabilise the protein structure, whilst ren-
dering the structure impervious to reduction. A challenge in di-
sulfide bridging is the tendency for disulfides to reform and
perhaps to scramble, and so Schumacher et al. used an in situ
approach, with TCEP present to prevent this. They observed
rapid conversion with a dithiophenylmaleimide&&, as well as
no TCEP-mediated cleavage, whereas TCEP–bromomaleimide
adducts were observed on treatment with dibromomaleimides.
In addition, bridging was successful with an N-functionalised
PEG dithiophenylmaleimide&& on the 14-residue peptide
hormone somatostatin, resulting in a dual-purpose modifica-
tion with a single reagent. The disulfide bridge in the hormone
is essential because it maintains a b-turn motif that mediates
binding interactions to &&G protein-coupled receptors ?
(GPCR, not GCPR)&&, but in its native form suffers from pro-
teolytic degradation and a short half-life in vivo. Therefore, PE-
Scheme 8. Protein modification with the aid of mono- or di-C-substituted&& maleimides.
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Gylation is useful for half-life extension, whereas disulfide
bridging &&infers “confers”?&& structural integrity.
Oxytocin is a peptide hormone known to help prevent post-
partum haemorrhaging after childbirth, but has a low solubility
and is prone to degradation, particularly at its disulfide bond.
This was replaced with a succinimide bridge in a process in
which the starting maleimide was functionalised with a poly-
mer; the combination aided in providing improved solubility
and increased stability at elevated temperatures.[109] A further
example of disulfide bridging in combination with polymer at-
tachment was demonstrated on salmon calcitonin, a 32-amino-
acid hormone, with a dithiophenylmaleimide&& polymer,
synthesised in a facile way in the absence of any protecting
groups.[110,111] The disulfide bridging strategy has been used to
synthesise antibody conjugates incorporating trastuzumab,
with other relevant moieties. Schumacher et al. prepared ADCs
containing trastuzumab and the cytotoxic drug doxorubicin,
targeting multiple interchain disulfide bonds,[112] and the meth-
odology has most recently been applied to MMAE (structure
shown in Scheme 5), with the resulting conjugate being fur-
ther hydrolysed to produce a serum-stable conjugate.[112]
CastaÇeda et al. also prepared trastuzumab–doxorubicin
conjugates, but included a benzyloxycarbonyl spacer between
the two components (Scheme 9).[113] This spacer is stable at
physiological pH, but not at acidic pH values, so drug release
at selected sites is possible. This might have application in
drug-release systems, for endosomal escape after ADC internal-
isation. The elegant concept was demonstrated by simply low-
ering the pH of the conjugate solution, and it remains to be
seen if it will be successful in cells and in vivo.
Bryden et al. reported the conjugation of trastuzumab with
a water-soluble porphyrin for photodynamic therapy (replacing
the disulfide bond linking the CL and CH1 chains).
[114] Hull et al.
illustrated the assembly of two different antibody fragments
by using a bis-dibromomaleimide linker, forming a homogene-
ous and bispecific construct, still capable of binding anti-
gen.[115] Schumacher et al. conjugated an scFv fragment to a C-
&&disubstituted maleimide containing a spin label.[116] As
well as conferring&& increased structural rigidity, the pres-
ence of the spin label also allowed EPR sensing of antibody–
antigen interaction, which could be useful in diagnostics and
therapeutics.
In an attempt to improve the half-life and stability of growth
hormone (GH) in circulation, researchers from Pfizer conjugat-
ed GH to aldolase antibody Covx.[117] Dual coupling has been
used to prepare ubiquitin–ubiquitin and ubiquitin–GFP conju-
gates; this emphasises the control possible by minimising the
number of equivalents used.[118]
Interestingly, Marculescu et al. have demonstrated the use of
aryloxymaleimides as improved reagents for disulfide bridging.
Their attenuated reactivity means that less monoaddition is en-
countered, and as an alternative application, a bromomaleimide
with an alternative functionality at the nitrogen can be added
after monoaddition, providing a facile method for dual modifi-
cation.[104]
Robin et al. made the rather interesting discovery that di-
thiomaleimides have emissive properties in certain solvents,
and these fluorescent agents can be conjugated to protein
partners in the presence of other useful groups, such as PEG,
thus giving another example of providing a dual function with
a single modification.[119]
As exemplified by the above examples, functionalisation of
maleimides at the N-position provides access to a range of in-
teresting groups, which also includes metallocarbonyl com-
plexes.[120]
The issue of reagent and conjugate hydrolysis is important
(Section 3.1.2). Hydrolysis leading to ring opening of the malei-
mide (applicable to both C-unsubstituted and C-substituted&
&) renders the reagent unreactive, whereas ring-opening hy-
drolysis after conjugation affords stable adducts. Ring opening
after conjugation might be preferred, particularly in therapeu-
tic applications, because the ring-opened form is not suscepti-
ble to GSH-mediated thiol exchange (Scheme 7). Ryan et al.
found that when N-phenyl-substituted maleimides were used,
hydrolysis could be induced post-conjugation by extended in-
cubation at pH 8 at varying temperatures. This is likely due to
the electron-withdrawing effect of the aryl moiety on the
ring.[121] This observation was further corroborated by another
study in which electron-donating N substituents (such as alkyl
groups) were found to minimise hydrolysis.[122] A further disad-
vantage associated with the use of maleimides is the retro-Mi-
chael reaction. Positively, conjugation with use of bromomalei-
mides is advantageous over that with use of unsubstituted
maleimides because this is not mechanistically possible.[112,123]
Scheme 9. Disulfide rebridging of trastuzumab and functionalisation with
doxorubicin and an acid-cleavable linker.
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3.3. Analogous structures
The same groups responsible for the development of the bro-
momaleimide platform reported on the reactions between cys-
teine and monobromo- and dibromo-1,2-dihydropyridazine-
3,6-diones (Scheme 10). The nitrogen atoms within the ring
were ethylated, because the presence of the protons led to
there being no reaction with cysteine, probably due to the
protons being too acidic at pH 8. The conjugates obtained
were found to be stable to hydrolysis, but susceptible to thiol
exchange and therefore cleavable under intracellular condi-
tions.[124]
A further development of this work involves a strategy for
rendering the conjugates resistant to thiol exchange.[125] On
the basis of the previous observation that reagents with un-
substituted nitrogen atoms within the ring were not reactive
at higher than physiological pH, Maruani et al. postulated that
the structure probably exists as its enol tautomer. They set
about devising a method for generating the enol tautomer
post-conjugation. This was achieved by attaching a para-azido-
benzyl group to a nitrogen atom within the ring susceptible to
thiol exchange. Quite simply, removal of this group (after con-
jugation to a protein) was carried out by treatment with TCEP
at pH 8 (Scheme 11). Cleavage of the para-azidobenzyl group
rendered the resulting conjugate insusceptible to thiol ex-
change with glutathione, which could be useful in applications
in which robust conjugates are required, such as in vivo imag-
ing. The fact that the nitrogen atoms need to be substituted is
a great advantage and allows a route to further decoration of
a protein with groups of interest. For example, the methodolo-
gy was applied to the functionalisation of the therapeutically
relevant Fab-Her2. Using a dibromopyridazine scaffold that
was functionalised through its nitrogen atoms with both
alkyne and cyclooctyne handles, &&Maruani et al. OK?&&
prepared antibody conjugates &&that contained various
combinations of a drug, a fluorescent marker and PEG, whilst
bridging unclear, please rephrase&&.[126] The methodology
provides a rather elegant method for what can be regarded as
a &&triple “quadruple-”?&&-purpose modification—disulfide
bridging providing increased stability of the antibody, func-
tionalisation with a drug for cytotoxic purposes, a fluorescent
marker for detection during cellular assays, or PEGylation for
increased half-life.
4. Disulfides
Two appropriately positioned cysteine residues within a protein
can oxidise to form an intramolecular disulfide bond—a modifi-
cation that is prevalent in the vast majority of proteins, playing
key roles in protein folding and structural integrity.[127] Crossed
disulfide bond formation has also been exploited as a chemical
modification method of choice for conjugation of proteins
bearing singly reactive cysteine residues to other thiol-contain-
ing moieties. Air oxidation is the simplest way to promote the
formation of disulfide bonds; however, this method does have
drawbacks including slow reaction times and an increased
chance of forming protein dimers (Scheme 12). This depends
Scheme 10. Modification of Grb-SH2 domain L111C with dibromo-1,2-dihydropyridazine-3,6-diones. Wild-type: PDB ID: 1JYU.
Scheme 11. TCEP treatment of GFP conjugate (wild-type: PDB ID: 1GFL) ren-
dering it insusceptible to thiol exchange.
Scheme 12. Common methods for disulfide formation.
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on the accessibility of the cysteine residue in question and is
difficult to control because the residue has to be somewhat ac-
cessible in order to be able to react with the desired reagent.
The use of activated reagents has proven paramount in the
continued use of disulfide bond formation, because they are
able to direct crossed disulfide formation.[128,129] In addition, the
use of activated reagents means that these reagents them-
selves are unable to form homodimeric structures. The use of
the Ellman reagent—5,5’-dithiobis(2-nitrobenzoic acid)—as an
indication of sulfhydryl content is a good example of the relia-
bility of certain activated agents because it is commonly used
for the activation of cysteine thiols on proteins for disulfide
bond formation.[130] The disulfide bonds formed by treatment
with the Ellman reagent have recently been used for the con-
struction of antibody–drug conjugates[131,132] and in an
enzyme-immobilisation strategy (Scheme 13).[133] In this exam-
ple, site-specifically grafting a dodecane chain onto BCL2 in
the presence of detergent resulted in an increase in enzymatic
activity due to mimicry of lipase interfacial activation exoge-
nously triggered by detergents. Similarly, 2,2’-dithiobis(5-nitro-
pyridine) (DTNP) can also be used as an activating agent in, for
instance, the ubiquitination of histones.[134]
Methanethiosulfonate reagents are well-established thiol-
coupling partners for disulfide bond formation, and are used
extensively in protein modification through cysteine
(Scheme 12). They are synthetically accessible and react selec-
tively with cysteine to yield disulfide bonds. The number of re-
ports in which methanethiosulfonate reagents have been uti-
lised is vast, and we do not provide an exhaustive list of stud-
ies carried out here. Some recent applications of the modifica-
tion, however, include the elucidation of protein function and
pathways,[135–139] EPR studies,[140] pull down/purification
assays,[29,141] the synthesis of polymer–protein conjugates for
improved therapeutic performance[142] and the construction of
protein conjugates with altered biological activities.[143]
Elaborate and efficient protecting group strategies for disul-
fide formation on peptides exist, and can allow good control,
but many are not applicable to proteins due to use of organic
solvents and sometimes microwave irradiation.[144]
Disulfide bonds are sensitive to reduction; this can be either
problematic or highly advantageous, depending on the desired
application. For applications in which a stable, irreducible
bond is required, multiple disulfide bridging techniques have
been developed (Section 3.2). Strategies for disulfide contrac-
tion, giving rise to irreducible thioether bonds, also
exist.[20,128,129]
Alternatively, the redox-sensitive nature of the disulfide
bond is useful in drug-delivery systems,[145–147] particularly
when a drug needs to be delivered into the cell. If a conjugate
consists of a cell uptake portion (e.g. , a cell-penetrating pep-
tide)[148] and a cytotoxic portion (e.g. , a small-molecule drug or
a peptide therapeutic) linked by a disulfide bond, this becomes
susceptible to reduction within the cell (containing elevated
levels of GSH). This can lead to drug release from lysosomal
compartments.
The site-specific sulfonation of cysteine was shown to result
in a functional redox-sensitive phosphoserine mimic, but the
protocol, albeit simple (addition of sodium tetrathionate and
sodium sulfite), would not be applicable to proteins with ac-
cessible disulfide bonds.[149]
5. Cysteine as a Precursor to Dehydroalanine
Dehydroalanine (Dha) is a naturally occurring amino acid pres-
ent in many proteins as a PTM at serine,[150] less commonly at
cysteine[151] and also in some peptidic antibiotic struc-
tures.[152–154] Dha is known to have a rigidifying effect on a pep-
tide chain, inducing or stabilising secondary structure and in-
creasing proteolytic stability. Chemically, it also provides
a unique electrophilicity that can be exploited by addition of
nucleophiles, in particular thiol groups, as extensively dis-
cussed below.
There are ample methods for incorporating dehydroalanine
into peptides and proteins by using serine as a precursor,[155]
but its use does have drawbacks. Serine has a higher natural
occurrence than cysteine, so site-selectivity is increasingly diffi-
cult to control. In addition, the potentially harsh conditions re-
quired to dehydrate serine—the use of H2O2, high pH values
etc.—might not be applicable to a wide range of proteins.
Cysteine as a precursor to Dha is less well-known than
serine on a natural level, yet its utility in chemical protein
modification is of high importance. Post-translationally intro-
duced Dha in &&microcystins? a microcystin?&& was re-
ported to “bind” to cysteine on a protein phosphatase, inhibit-
ing its activity, yet demonstrating the ability of the thiol group
of cysteine to react with Dha.[152] Despite the fact that various
reports involve the use of Dha in peptide and protein modifi-
cation, its potential (as a precursor to further selective protein
modification) has only really been realised in recent years, par-
ticularly since the Davis group reported the use of a generally
applicable reagent for forming Dha from a cysteine precursor
(Scheme 14).[155] This method is more facile and economical
and less time-consuming than the use of serine as a precursor.
5.1. &&Transformation of cysteine residues into Dha resi-
dues OK?&&
A study on different methods for converting cysteine into de-
hydroalanine was carried out by the Davis group
(Scheme 14).[155] Methods for this transformation that had been
Scheme 13. Crossed disulfide formation mediated by Ellman’s reagent. &
&no number next to brackets–?&&
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reported earlier involved the use of conditions incompatible
with many proteins, such as high temperatures[156] and high
proportions of organic co-solvents.[157] DuMond et al. observed
unintentional Dha formation from cysteine on using HNO
donors.[158] Tedaldi et al. reported that Dha could be formed at
an amino acid level through an addition/elimination sequence
of a bromomaleimide with the thiolate ion and subsequent
base-mediated elimination of the resulting thiomaleimide
bond.[102] This methodology was, however, not successful in
aqueous medium and has not been applied to proteins since.
The aim of the study carried out by the Davis group was to
find a reagent for the modification that could be applied to
a wide range of proteins &&without problems of stability or
use of organic co-solvent, operating at ambient temperatures
and pH, and providing chemoselectivity OK?&&. Although
Cys-to-Dha conversion in a selective manner was previously
found to be possible in the case of a single cysteine mutant of
the robust subtilisin Bacillus lentus (SBL-156C) in DMF with use
of O-mesitylenesulfonylhydroxylamine (MSH),[159] it was found
to be unsuccessful with other proteins.[155,160] In the SBL-156C
case, however, Dha produced by treatment with MSH has
been used as an orthogonal handle in the first example of
cross-metathesis on a protein,[161, 162] radiolabelling with 18F-con-
taining sugars[163] and the synthesis of homogenous glycocon-
jugates.[164,165]
One alternative method for forming Dha from cysteine was
by a &&dialkylation/elimination method with the diamide
OK?&& based on a 1,4-dibromobutane core (2,5-dibromohex-
anediamide&&2,5-dibromohexanedioic acid diamide?&& ),
through which conversion into Dha could be carried out on
three proteins, including an antibody (Scheme 14). The reac-
tion was selective at the desired cysteine residue despite
others being present (albeit in disulfide bonds), and the anti-
body was found to retain secondary structure. Although the
reagent is only partially soluble in water, the reaction could be
carried out in the absence of organic solvent. It proceeds
through dialkylation/elimination&&, with the pre-elimination
intermediate (cyclic or linear) identifiable by LC/MS. A slightly
elevated &&pH (8) OK?&& is required for the reaction, but
this is not detrimental to the vast majority of proteins, and an
increment of temperature to 37 8C is sufficient for elimination
to form Dha. Also, because the pKa of the thiol proton varies
from cysteine residue to cysteine residue, depending on its mi-
croenvironment,[16] reaction at a lower pH can be possible.
Over the last few years, the reaction has been applied to
a range of proteins, followed by Michael-type addition of thiol
moieties, both by the Davis group and by others.[155,166–169]
There are a few perceived issues associated with the use of
Dha as a precursor.[170] The introduction of an sp2-hybridised
carbon causes the chiral centre to be lost, and so diastereo-
meric products can be obtained after addition. The stereo-
chemical outcome can be difficult to predict unless protein
crystal structures are available, to provide a 3D view of which
direction addition would be less hindered. Aydillo et al. devel-
oped a synthesis of a chiral Dha amino acid derivative from
a cysteine precursor based on a chiral auxiliary approach, and
then allowed this to react with thiosugars, achieving high dia-
stereoselectivity.[171] These derivatised amino acid building
blocks can be used in solid-phase peptide synthesis, or per-
haps even combined with an NCL strategy for protein synthe-
sis, thus avoiding the creation of diastereomers. However, at
a protein level, this might not be required, because neighbour-
ing and &&proximate “proximal”?&& residues might them-
selves act as auxiliaries, promoting attack from one face. A
wealth of functionality is possible, with introduction of both
natural and unnatural functionalities, as well as mimics of func-
tionality, all via the same orthogonally reactive handle—
Dha.[155,172] Moreover, Dha is prone to hydrolysis, but because
the transformation from Cys into Dha takes a few hours at
most for the majority of tested substrates, further reaction can
then be carried out, affording stable modified protein within
a day. This method of chemical post-expression installation
under ambient conditions is advantageous over genetic instal-
lation in this respect, because no manipulation of cell machi-
nery is required.
5.2. Application of modifications via Dha
Once incorporated in a protein, a Dha residue is susceptible to
nucleophilic attack by a thiol moiety. This has been exploited
to form PTM mimics, in which a conventional O-link is replaced
by an S-link. Chalker et al. , for example, synthesised methylat-
ed and acetylated lysine mimics on histone H3 by use of Dha,
detectable by western blot with antibodies raised against the
natural O-linked modification,[166] and Chooi et al. successfully
switched protein kinase to an active state by incorporating
phosphocysteine (pCys) via Dha (Scheme 14).[167] The presence
of this mimic led to phosphorylation of the natural substrate
ATF2, thus chemically recapitulating triggering of the MAPK-
signalling pathway in vitro. Blagg’s lab have used the same
methodology to elucidate the necessity of two different phos-
phorylation sites on protein kinase aurora-A.[173] As well as for
Scheme 14. Dehydroalanine formation followed by further protein function-
alisation. Single-domain antibody cAb-Lys3: PDB ID: 1MEL. p38a : PDB ID:
1R3C.
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the formation of PTM mimics, Dha has been used as a handle
on various proteins to incorporate both sulfur- and selenium-
containing groups suitable for subsequent metathesis
(Scheme 14).[168] Additionally, Timms et al. tested the effect of
thialysine in place of native lysine on the activity of the protein
N-acetylneuraminic acid lyase.[174]
Back in the Davis group, Gunnoo et al. synthesised an AND-
gated antibody of the single-domain antibody cAb-Lys3, in
which antibody function was dependent not only on antigen
but also on a PTM-processing enzyme, a phosphatase. By in-
corporation of pCys via Dha within the CDR3 loop of cAb-Lys3,
antigen-binding ability was turned off. This effect on the addi-
tion of various phosphatases was reversible, and the antibody
was able to bind again (Scheme 14). The AND gate was dem-
onstrated both in vitro and in mammalian tissue. Phosphorylat-
ed antibody was able to bind selectively to cells expressing
cell-surface antigen only when phosphatase (either exogenous
or endogenous) was present.[169] This strategy of reversibly in-
hibiting antibody function by a combination of chemical and
enzymatic modification might be applicable in antibody thera-
peutics, reducing side effects caused by antibody binding to
cell-surface antigen in healthy tissue.[175]
In terms of PTM mimics, S-linked PTMs are naturally occur-
ring, and so thiol addition to Dha will not always result in
a structural mimic.[18] The chemical introduction of S-linked
PTMs allows a facile method for exploration of the modifica-
tion. In addition, S-linked glycoconjugates are in fact desirable
in drug strategies because they are known to be resistant to
enzymatic processing—by glycosidases, for example—whereas
thiophosphate can be processed by the more promiscuous
phosphatases.[169]
There are examples of the use of Michael addition of thiols
to Dha in which the aim is not to introduce PTM mimics. Haj-
Yahya et al. , for instance, synthesised a diubiquitin-based
probe to study the activity of deubiquitinases through the
chemical installation of Dha.[176] The dibromo-mediated conver-
sion of cysteine into Dha in soluble proteins and membrane
proteins was monitored by Branigan et al. , to test the efficien-
cy of a cysteine quantification protocol involving thermally in-
duced protein folding and conjugation to a fluorogenic com-
pound through alkylation.[177] It was observed that elimination
to yield Dha could be slow, leaving the sulfonium intermediate
(Scheme 14), as detected by LC/MS.
This was used by Nathani et al. as a positive point for further
or dual functionalisation of a protein (Scheme 15).[178] With GFP,
the cyclic sulfonium intermediate was found to be stable and
to persist for 4 h at 37 8C or for 24 h at 21 8C. Immediate func-
tionalisation by ring opening mediated by a nucleophile was
therefore required to maximise modified protein recovery. A
range of nucleophiles were effective, and included other bioor-
thogonal handles such as an azide. The stability of the sulfoni-
um ring could probably be attributed to the environment sur-
rounding the site of modification. This was extended further in
a dual-labelling strategy, taking advantage of the differential
reactivity of two cysteine residues within GFP. One cysteine res-
idue was converted into Dha by use of the dibromo reagent
(and modified further with thiol nucleophiles), whereas the sul-
fonium adduct formed from the other cysteine residue was fur-
ther functionalised with an azide nucleophile and then with an
&&alkyne-appended fluorophore OK?&&.[179] In this strategy,
in which two cysteine residues were essentially treated as dif-
ferent amino acids, the challenge lay in having and identifying
two cysteine residues that exhibited essentially orthogonal re-
activity within a protein, thereby avoiding the creation of mix-
tures of modified products. Although thiol nucleophiles are
very good partners for Michael addition to Dha in terms of
ease of reaction, resulting conjugate stability and function, the
ability to apply other reactions, perhaps forming carbon–
carbon bonds, would be desirable.[170]
6. Thiol-Ene and Thiol-Yne Reactions
The widely used thiol-ene reaction is a reaction between
a thiol and alkene, and is commonly radical-mediated, thus re-
quiring irradiation&&please confirm&&. Photoinitiation gen-
erates the thiyl radical, and propagation then consists of
alkene addition and protonation. The process is terminated by
disulfide formation between two thiyl radicals, this can be re-
versed by the addition of a reducing agent (Scheme 16).[180–182]
The reaction, which meets many requirements of a “click” reac-
tion, has been exploited extensively in polymer chemistry.[183] It
is orthogonal, does not require organic solvent in order to pro-
ceed and is rapid in most cases, criteria that make it an attrac-
tive choice for site-selective biomolecule modification. Further-
Scheme 15. Trapping of an intermediate on treatment of cysteine with 2,5-dibromohexanediamide and a nucleophile. GFP: PDB ID: 1GFL.
Scheme 16. Thiol-ene reaction mechanism.
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more, it is fully compatible with water and oxygen, a highly at-
tractive feature for protein modification. However, some pro-
teins are unstable to the UV irradiation conditions required for
radical generation, despite it being a relatively low-energy
(365 nm) process. This has not precluded its application to pro-
tein modification, and, depending on the protein substrate,
UV-mediated modification can result in a functional conjugate.
Some proteins’ lack of tolerance towards irradiation does
mean that it would be difficult to present the thiol-ene reac-
tion as a generally applicable strategy.[184]
Recent protein modification work utilising the thiol-ene reac-
tion tends to follow one of two routes—either the alkene is in-
corporated pre- or post-translationally[185] and then treated
with a thiol-derivatised group of interest, or an alkene-deriva-
tised group of interest is conjugated to a cysteine within the
protein. Because this review concerns modification through
cysteine, we focus more on studies in which cysteine has been
employed as an orthogonal handle for the thiol-ene reaction,
and discuss why researchers would choose to incorporate an
unnatural alkene instead of using the natural cysteine handle,
in discussion of examples in which proteins have been em-
ployed.
6.1. Thiol-ene reaction with proteins
The photodegradation of proteins by UV irradiation is widely
documented.[184,186] The excitation of aromatic residues pro-
motes electron transfer to proximal disulfide bonds, thus caus-
ing cleavage. Dondoni et al. glycosylated BSA (bovine serum
albumin) containing one disulfide bond and one free cysteine
residue through a thiol-ene reaction at 365 nm, and found that
after a short while all three cysteine residues were glycosylated
(Scheme 17). They clarified that the protein was intact by
MALDI analysis, but site-specificity was not achieved.[186] This
observation reduces the generality of the thiol-ene reaction,
because intact disulfide bonds are not necessarily tolerant to
irradiation conditions. However, it is important to note that
finding chemical modification strategies applicable to a multi-
tude of proteins is very challenging.
An example of thiol-ene protein modification through an
alkene unit within the protein is the glycosylation of the virus-
like nanoparticle ssbG with the aid of genetically incorporated
homoallylglycine (Hag) residues. The thiol-ene reaction itself
was carried out at pH 4–6, and so might have potential in se-
quential dual-modification strategies, but both cysteine and
methionine residues were mutated out of the protein, thus re-
ducing its utility as a site-specific and selective modification.[187]
Weinrich et al. incorporated a farnesyl group into &&a pro-
tein/proteins and used the alkene group to immobilise this
protein/these proteins&& onto surfaces coated with thiol
groups.[188] Another example of the thiol-ene reaction on pro-
teins incorporating an alkene tag is provided in work by Li and
co-workers.[185] They genetically incorporated alkene-bearing
pyrrolysine analogues into the proteins HdeA and AsnII in Es-
cherichia coli by use of a mutant PylRS-tRNA pair.[7] They al-
lowed these to react with bi-dansyl-cystamine and PEG-bearing
thiols, with varying yields, with the aid of the radical initiator
Vaso44 and irradiation at 365 nm. The bioactivity of the pro-
teins after conjugation was tested and was found to be re-
tained. AsnII contains three free cysteine residues, and al-
though the authors could see, by means of a fluorescent gel,
that the fluorophore had conjugated, mass spectrometry and
enzymatic digests were able to establish with certainty that
there is no crossreaction with cysteine residues. Li et al. argue
that if more than one cysteine is present in a protein, the
thiol-ene reaction cannot be carried out. This is not necessarily
true, and strongly depends on the microenvironment and ac-
cessibility of the cysteine residues, factors that need to be de-
termined with each protein.
Further examples of thiol-ene conjugation based on natural
cysteine residues do exist. Li et al. allowed cysteine residues on
ubiquitin and histones H3 and H4 to react with N-vinylaceta-
mide, forming functional post-translational mimics
(Scheme 17),[189] whereas Valkevich et al. used the reaction to
form ubiquitin trimers in order to gain insight into ubiquitin’s
biological function.[190] A paramagnetic lanthanide ligation
partner was synthesised and ligated to an E. coli arginine re-
pressor and ubiquitin through cysteine (Scheme 17). The con-
jugates could be useful in NMR analysis. Interestingly, no radi-
cal initiator or light was used and around 80% conversion was
achievable in 24 h. Although the reaction time is quite long,
the lack of irradiation is an impressive feature of the reaction,
which probably proceeds through Michael addition with the
aid of the adjacent conjugated system in the compound.[191]
Ma et al. have recently carried out kinetic studies in relation to
substrate choice for the thiol-ene reaction. When vinyl-substi-
tuted pyridine derivatives are used, the protonation of the pyr-
idine N is of importance in terms of rate acceleration. Similarly,
a,b-unsaturated alkene systems are useful in potentially allevi-
ating the need for radical formation.[192]
A further interesting example of the use of the thiol-ene re-
action is the incorporation of photoswitchable amino acids
bearing alkene groups that are able to react with cysteine
when appropriately positioned in peptides.[193] &&A related
approach, but utilising SN2 substitution of a photoswitchable
group with cysteine (rather than the thiol-ene reaction as had
been carried out on peptides), was found to be suitable for in-
ducing changes in protein conformation OK?&&.[194]
Scheme 17. Alkene-containing partners for thiol-ene reactions with cysteine
residues in proteins.
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6.3. Reactions between cysteine residues and alkynes
The reactions between thiols and alkynes have long been
known, but in more recent years their applicability to protein
environments through cysteine has been explored. Most re-
searchers are aware of the famous copper-catalysed azide–
alkyne cycloaddition (CuAAC),[183] but not that alkynes are also
reactive towards thiols. Crossreactivity with cysteine thiols
when carrying out CuAAC is not often observed (although it
has been reported and/or speculated on and is dependent on
the inherent reactivity of the alkyne).[195–197]
Alkynes and thiols can be conjugated with the aid of light ir-
radiation (Section 6.4), but as Shiu et al. have described exten-
sively, this is not necessary despite the weakly electrophilic
nature of the alkyne functionality. They have described the ad-
dition of electron-deficient alkynes (alkynoic amides, esters and
alkynones) to unprotected peptides and BSA in aqueous solu-
tions (albeit with 10% CH3CN) to target cysteine residues, re-
sulting in vinylsulfide linkages (Scheme 18).[198] The selectivity
and efficiency of the conjugation was demonstrated by the en-
richment of cysteine-containing peptides in a solution contain-
ing peptides with and without cysteine residues. Previously,
the corresponding reactions of electron-deficient alkynes had
been carried out with “simple” thiols (namely cysteine and glu-
tathione) in the presence of organic solvent.[199,200]
Depending on the alkyne used, the vinylsulfide linkage can
be cleaved by the addition of a thiol. This observation was
used to develop FRET-based fluorescent[201] and luminescent
probes.[202] In the latter example, the alkyne groups are at-
tached to an iridium(III) complex. In a more recent example,
the same group has demonstrated the attachment of phos-
phorescent IrIII complexes appended to an alkynoic amide to
peptides and proteins. The resulting conjugates display long
emission lifetimes and large Stokes shifts, and might therefore
be useful in cell-imaging studies.[203]
Ekkebus et al. incorporated a propargylamide group onto
the C terminus of ubiquitin as a cycloaddition handle,[204] and
unexpectedly observed irreversible inhibition of corresponding
deubiquitinases—which, incidentally, were cysteine proteas-
es—at stoichiometric amounts (Scheme 19). Cysteine was
found to be the site of attachment for the alkyne, as support-
ed by several pieces of experimental evidence, such as by
competition experiments with N-ethylmaleimide, and also by
solving of the crystal structure of the enzyme·substrate com-
plex. The crystal structure revealed that the terminal alkyne
can react with cysteine within the protease active site, which is
lined with multiple partial positive charges of hydrogen-bond-
donor groups, thus creating an environment favouring the re-
action transition state, leading to the formation of a quaternary
vinyl thioether (Scheme 19). The reaction is completely depen-
dent on the presence of the enzyme, because the C-terminal
alkyne is unreactive towards thiols in excess and towards other
cysteine residues within proteins. Sommer et al. made similar
observations in a report published soon after, with SUMO (a
ubiquitin-like protein) and ubiquitin.[205] They reported the high
specificity of the reaction, and deduced that it was driven by
the close proximity and alignment of the alkyne and the thio-
late ion in the enzyme oxoanion hole, hence driving the reac-
tion forward. This remarkable discovery of irreversible inhibi-
tion of cysteine proteases in such a selective manner might
find use in activity-based protein probes, potentially for many
protease–substrate partners.[206, 207]
6.4. Radical-mediated thiol-yne coupling
The photoinitiated thiol-yne reaction, which can be considered
the “sister” reaction of the thiol-ene reaction, ordinarily results
in two thiol groups adding across a single alkyne, which leads
to functionalisation in a multivalent fashion (Scheme 20). After
irradiation between 254–470 nm (UV/Vis range), the thiyl radi-
cal adds to the triple bond to give an intermediate vinyl thio-
ether that then undergoes a second (faster) thiyl radical addi-
tion (formally a thiol-ene reaction) to yield a dithioether with
exclusive 1,2-addition (Scheme 20). Once again, the reaction is
prevalent in polymer synthesis, and its multifunctional nature
has led to applications in supramolecular chemistry, dendrimer
synthesis and the immobilisation of various materials.[208–211]
Scheme 18. Reactions between cysteine residues and electron-deficient al-
kynes.
Scheme 19. Cysteine proteases react with alkynes.
Scheme 20. Thiol-yne reaction mechanism. &&please explain back-facing
arrow bottom right&&
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The requirements for a radical initiator and/or irradiation have
minimised its application to protein chemistry, due to worries
about protein stability under such conditions.
In the context of proteins, BSA has been dually functional-
ised through its cysteine residues[196] (including through
a native disulfide bond as a result of irradiation, as observed
previously[186]), and Li et al. opted to incorporate an alkyne
handle genetically for reaction with bi-dansyl-cystamine in an
analogous fashion to an alkene handle described previously.[212]
The thiol-yne reaction has been applied less than other meth-
ods to proteins through cysteine, but further understanding of
it by, for example, the publication of studies into optimisation
of conditions and reaction outcomes[213] might lead to wider
uses as a facile method for dual functionalisation of a protein.
7. Use of Metals in Cysteine Modification
Metal-mediated conversions are widespread in organic chemis-
try; &&certain OK?&& metals’ high functional group toler-
ance means that they can be employed in synthetic steps in-
volving substrates containing multiple functionalities. Histori-
cally, the use of metals in chemical protein modification has
been quite uncommon, and there are worries about perceived
toxic effects of certain metals in vivo, meaning that intra- or
extracellular modifications might not be feasible.[214,215] Howev-
er, protein modification strategies are useful outside of the
body too, such as in the construction of antibody–drug conju-
gates[2] or for radiolabelling prior to patient administration.[216]
In fact, selective reactions at cysteine are not best suited for in
vivo transformations, due to the presence of exofacial and
plasma thiols.[217] Previously, metal-mediated reactions activat-
ing otherwise inert endogenous amino acids had been devel-
oped, resulting in the addition of reactions to the protein
modification “toolbox”.[218–220] Sulfur atoms within cysteine resi-
dues are capable of binding to a wide range of metal ions, in-
cluding iron, zinc and cadmium (namely soft metal cen-
tres).[19,221] Protein immobilisation onto gold plates through
cysteine residues for surface plasmon resonance (SPR) is well
established.[222] Sulfur’s affinity towards metals has contributed
to cysteine being used in thiol protection strategies and metal-
mediated modifications.
7.1. Metal protection
Many have addressed the need for multiple modifications
within a single protein by use of unnatural amino acids,[223] but
Smith et al. took a different approach—independently labelling
multiple thiols by using sufficiently differentially reactive cys-
teine residues. The differential reactivity was achieved by rever-
sible protection of cysteine residues through metal coordina-
tion. Maltose-binding protein (MBP) containing a fused
Cys2His2 zinc finger domain together with a single additional
cysteine residue was functionalised with two different malei-
mide-containing fluorophores. Zinc was added, temporarily
blocking the reactivity of the cysteine residues within the zinc
finger domain whilst the free cysteine was functionalised, and
then the zinc was removed, and the remaining cysteine resi-
dues were functionalised.[224] &&Smith et al. OK?&& also
used the technique to immobilise glucose-binding protein
(GBP) onto glass slides. A recent publication reports the use of
the coordination of Zn2+ ions to the Cys2His2 motif to alkylate
another free cysteine for the synthesis of DNA-binding zinc
finger conjugates.[225] In this study, the purpose of Zn coordina-
tion was twofold—it blocked the cysteine residues’ reactivity,
but also behaved as a folding agent, assembling the DNA-
binding portion (Scheme 21).
Kuiper et al. used a similar strategy but protected two vicinal
thiol groups (spaced 6.3–7.3  apart) with phenyl arsenic
oxide, whilst engaging a free cysteine in reaction in sulfate-
binding protein from Salmonella typhimurium.[226] Two thiolate
groups are able to form a high-affinity ring structure with
phenyl arsenic oxide, which is removable by DTT (Scheme 22).
Significant engineering to find optimal conditions for forming
the complex was required in the study, but these might also
be applicable to other protein substrates to which the method
might be applied, with the exception of those containing sol-
vent-exposed disulfide bonds. Puljung et al. have also used
metals in a protective way.[227, 228] They found that the microen-
vironment of the cysteine is what defines its affinity towards
metals. It is increased by incorporation of cysteine into minimal
binding sites in existing secondary structural motifs, so reactivi-
ty can be tweaked.
7.2. Mediation by metals
An emerging field involves the use of metals as mediators for
selective modifications at cysteine. Chan et al. demonstrated
Scheme 21. Protection and folding with the aid of Zn2+ . Taken from Rodri-
guez et al.[225]
Scheme 22. Thiol protection with phenyl arsenic oxide, leading to modification through cysteine with two different groups.
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gold-mediated oxidative allene–thiol coupling on proteins
under mild reaction conditions, forming hydroxy vinyl thioeth-
ers (Scheme 23).[229] The gold activates the p system of the
allene. The proposed mechanism is the formation of a thiol-
ene radical intermediate that is generated by the reaction of
the gold compound, the allene and the thiol. The seemingly
anomalous hydroxy group is probably obtained through cap-
ture of molecular oxygen, hydrogen atom transfer and dispro-
portionation (Scheme 23).
Gold has also been used for selective modification at cys-
teine through well-defined complexation. Cysteine is reported
to interact with cyclometallated gold(III) complexes in cancer
cell lines,[230] and Kung et al. used this observation to carry out
ligand-controlled carbon–sulfur bond formation by use of cy-
clometallated gold(III) complexes with bidentate C,N-donor li-
gands and ancillary ligands.[231] After complexation, reductive
elimination yielded the alkylated cysteine. Although impressive
work, the compatibility of the gold complexes with bio-macro-
molecular systems is questionable. The large and hydrophobic
gold substrates are probably insoluble in aqueous systems;
hence the use of 90% DMSO solution for the modifications of
BSA and human serum albumin (HSA). Improvements to the
aqueous solubility of the modification reagent might help
make the procedure more general.
Rhodium-catalysed transformation at cysteine by its alkyla-
tion through SH insertion of a metallocarbene intermediate
(formed by reaction between a rhodium complex and a diazo
reagent, Scheme 24) is possible. The thioether linkage formed
on the protein cystic fibrosis transmembrane conductance reg-
ulator-associated ligand and its PDZ domain (CALP) was found
to be more stable than thiosuccinimide linkages (formed by re-
actions with maleimides, Section 3) in human plasma serum,
indicating potential applicability in a therapeutic context. How-
ever, the method’s generality is restricted by crossreaction with
solvent-exposed tryptophan, which can perhaps be alleviated
by mutagenesis to an amino acid that is inert under the reac-
tion conditions.[232]
Most recently, Vinogradova et al. have described the aryla-
tion of cysteine residues for peptide stapling and in the con-
struction of ADCs with the aid of palladium(II) complexes
(Scheme 25).[233] Pd and thiol reagents had previously been
considered incompatible, owing to observations of Pd-cata-
lysed cross-couplings being inhibited by thiols and of PdII com-
plexes exhibiting protease-like behaviour. The researchers alle-
viated these factors by careful choice of ligand, and reported
rapid conversions (<30 min) into arylated biomolecules under
mild conditions with peptides, proteins (antibody mimetics)
and the therapeutically relevant antibody trastuzumab.
The use of metals in cysteine-based protein modification is
both underdeveloped and exciting. The use of metal-mediated
“protection” still allows a cysteine residue to be used as
a uniquely reactive handle, despite the presence of other cys-
teine residues. It remains to be seen whether metal-mediated
reactions, newly applied to proteins, will be useful for further
applications, largely due to solubility issues.
8. Miscellaneous
8.1. Thiazolidine formation
A thiazolidine is formed by condensation between amine and
thiol on the same entity with an aldehyde or ketone. A cys-
teine residue at the N terminus of a protein is itself a 1,2-ami-
nothiol, and can be conjugated to an aldehyde-bearing
moiety, as demonstrated by Casi et al. with the clinical stage
human antibody F8 and the cytotoxic drug cematodin
(Scheme 26).[234,235] The reaction is a clever demonstration of
orthogonality with an endogenous amino acid. Because an
Scheme 23. Gold-mediated coupling of proteins with allene compounds.
Scheme 24. Rh-mediated cysteine modification.
Scheme 25. Pd-mediated cysteine arylation.
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amino group is required for reaction, only an N-terminal cys-
teine is reactive, thus making mutation of other cysteine resi-
dues within the sequence (if present) unnecessary. Because
methionine is the first amino acid incorporated during protein
biosynthesis, incorporation of an appropriate upstream cleava-
ble amino acid sequence is required. The obtained ADC exhib-
ited favourable properties as a releasable, and therefore sepa-
rable, conjugate in vitro, regenerating the cysteine and alde-
hyde, thus leading to drug release. However, there is prece-
dence that intracellular oxidation of aldehydes to their corre-
sponding carboxylic acids might have a cytotoxic effect,
specifically in cancer stem cells.[234]
As an alternative conjugation strategy, the authors proposed
that a C-terminal cysteine can be induced to react with a heter-
obifunctional maleimide-thiazolidine reagent and that the thia-
zolidine can be deprotected with methoxyamine and then in-
duced to react with an aldehyde-bearing moiety.[234] This strat-
egy is also relevant to internal cysteine residues. This second
strategy requires more steps, which is disadvantageous, espe-
cially in view of the wealth of maleimide-modified conjugation
partners available. However, maleimide-functionalised reagents
are prone to hydrolysis (converting them to an unreactive
state), whereas aldehydes are not, yet the second strategy de-
pends on maleimide–thiol coupling. One could argue that use
of the aldehyde portion is unnecessary if coupling is to be car-
ried out through a maleimide–thiol reaction, and that a malei-
mide-modified drug would suffice. For applications in which
a stable linkage is required—for in vivo imaging or diagnostics,
for example—thiazolidine formation would be unsuitable, due
to the instability of the ring.[236]
8.2. Reactions with aryl sulfones and &&similar reagents
OK?&&
Cysteine residues within proteins can also be induced to react
selectively with functionalised sulfone reagents through Mi-
chael addition for the purpose of improving therapeutic effica-
cy through, for example, PEGylation. Shaunak et al. used the
a,b-unsaturated b-monosulfone with PEG to bridge disulfides
and to PEGylate proteins simultaneously.[237] The reaction is
a sequential addition/elimination process and is initiated by
thiol addition to the double bond, followed by sulfinic acid
elimination, and then by addition by another thiol. The same
dual-purpose functionalisation can also be carried out with a la-
tently reactive bis-sulfone, in which elimination of the sulfinic
acid occurs in situ, generating a reagent suitable for nucleo-
philic attack by a cysteine thiol (Scheme 27).[238] Pfisterer et al.
synthesised bis-sulfones also containing iodine or ethynyl moi-
eties and conjugated these to the disulfide bridge of somatos-
tatin.[239] Wang et al. used the same bis-sulfone scaffold with
the R group being a drug or fluorophore to bridge the disul-
fide bond of somatostin. The resulting bridged conjugate was
intact when incubated with low concentrations of GSH, but re-
ducible at higher levels, thus showing potential for release in
intracellular tumour delivery systems.[240] An impressive exam-
ple exhibiting the versatility and tuneability of cysteine conju-
gation was demonstrated by the same group,[241] who synthes-
ised a thiol-reactive cross-conjugation partner containing a mal-
eimide group at one end and a bis-sulfone at the other. At
a lower pH, the bis-sulfone remains intact and reaction pro-
ceeds between the first bio-macromolecule and maleimide.
Then, at pH 8, the bis-sulfone is reactive, allowing conjugation
to the second bio-macromolecule. A recent publication on bis-
sulfones as disulfide “intercalators” further emphasises the
broad applicability of this approach.[242] Badescu et al. further
developed a monosulfone conjugation partner in which the
conjugate has increased stability. After conjugation to a single
cysteine residue, the carbonyl group adjacent to an aryl group
can be reduced &&with a hydride to afford an alcohol that is
not susceptible OK?&& to elimination at a neutral pH.[243]
Zhang et al. reported on MSBT (2-(methanesulfonyl)benzo-
thiazole) as a cysteine-blocking reagent for analytical purpos-
es.[244] They proposed that the ring portion of MSBT would be
susceptible to nucleophilic attack in the presence of a suitable
adjacent leaving group (Scheme 27). After tests at a small-mol-
ecule level, they tested reactivity on a protein, and found by
western blot detection after a biotin-switch assay that cys-
teine(s) had been blocked. Although no further clear experi-
mental evidence was delivered, Toda et al. were inspired by
this strategy, and showed that a range of heteroaromatic rings
could be employed for efficient and selective cysteine modifi-
Scheme 26. Antibody modification based on use of an N-terminal cysteine
residue and an aldehyde.
Scheme 27. Sulfone conjugation partners.
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cation (Scheme 27). They used the methodology to modify
HSA with PEG and fluorophore moieties.[245] Patterson et al.
treated a phenyloxadiazole sulfone drug with the antibody
trastuzumab, resulting in an ADC with improved plasma stabili-
ty relative to the maleimide-linked drug (Scheme 27).[246] Final-
ly, a fluorescein-derivatised phenyloxadiazole sulfone has re-
cently been employed in a dual modification strategy of anti-
bodies.[247]
8.3. Reactions with vinylsulfones
Masri and Friedman described Michael addition between cys-
teine and aliphatic vinylsulfones on BSA and wool in 1988.[248]
They found that crossreactivity with nucleophilic histidine and
lysine amine groups could be avoided by lowering the reaction
pH. In addition, a smaller amount of equivalents of reagents
minimises crossreactivity with lysine and histidine residues,
which is beneficial from an economic point of view.[249] The
conjugation has potential wide applicability as a general
method for selectively modifying proteins because it can be
carried out under ambient conditions and does not require
any catalysts or produce by-products. The thioether bond
formed is stable, and the vinylsulfone itself is more stable in
storage than the hydrolysis-prone maleimide.
Morpurgo et al. tested the potential of the reaction for ap-
plied research by PEGylating ribonuclease with a vinylsulfone-
functionalised PEG moiety.[250] Vinylsulfones derivatised with
relevant and varied groups are synthetically accessible, and in
recent years this reaction has been described for a wealth of
applications, covalent protein immobilisation in particu-
lar.[251,252] In addition, more sophisticated compounds contain-
ing two orthogonally reactive groups can be prepared, allow-
ing dual modification.[253] Ortega-MuÇoz et al. described the
synthesis of vinylsulfone-functionalised silica and subsequent
immobilisation of cysteine-containing enzymes.[254] The hy-
droxy groups of the silica support could be functionalised with
vinylsulfone groups in two steps, ready for reaction with cys-
teine-containing biomolecules. The authors state that as well
as cysteine, lysine and histidine residues are also reactive; how-
ever, their immobilisation procedure is carried out at pH 7.5,
and no direct determination of exactly by which residues the
enzymes are immobilised was carried out. For the purposes of
this application, control of site- and residue-specificity is para-
mount in order to avoid loss of biological activity on immobili-
sation. Despite this, in a later study, plant thioredoxins were
covalently immobilised onto vinylsulfone-functionalised silica
resin prior to successful investigation of their functions.[255] Fur-
thermore, proteins can be immobilised onto super-paramag-
netic nanoparticles functionalised with vinylsulfone groups.[256]
Stanley et al. have recently described the use of a tosyl-sub-
stituted sulfone bearing an adjacent electron-withdrawing
group. Initial reaction with a cysteine results in an activity-
based probe bearing a vinylsulfide linkage, which can then un-
dergo further reaction with a proximal thiol in an irreversible
fashion. This methodology can be used to profile transthiola-
tion activity.[257]
8.4. Reactions with 2-cyanobenzothiazoles
Rao’s group reported on the condensation reaction between
an N-terminal cysteine residue and a 2-cyanobenzothiazole (2-
CBT) to form a luciferin core linkage in 2009 (Scheme 28). The
reaction is rapid in nature and proceeds under mild conditions
suitable for chemical protein modification.[258] Site-specificity
was further confirmed by specific labelling of proteins &
&containing N-terminal cysteine residues expressed on cell
surfaces OK?&&.[259] The fact that the reaction only works
with an N-terminal cysteine residue is both an advantage and
disadvantage. On one hand, it allows selectivity even in the
presence of native cysteine residues, yet the N-terminal cys-
teine residue needs to be engineered in because methionine
residues are the normal N-terminal residues. This can be car-
ried out by expressed protein ligation (EPL) through fusion to
an intein and subsequent pH-induced cleavage,[260] or by ex-
pression with a protease cleavage site such as in tobacco etch
virus (TEV) protease.[259,261] The reaction has proven to be quite
versatile and has been used for the covalent immobilisation of
peptides and proteins on 2-CBT-functionalised microar-
rays[260,261] and for the labelling of proteins with 18F for tumour
imaging by PET,[262] amongst others. In a xenograft mouse
model, a good tumour-to-background contrast was obtained,
with the exception of high accumulation in the liver; this can
be attributed to the lipophilicity of the obtained luciferin link-
age and can probably be modified by chemical manipulation
of the 2-CBT reagent. For more details and applications of this
reaction to proteins, readers are referred to a recent review.[263]
Most recently, the reaction has been employed alongside
other orthogonal chemistries for the bridging of cells.[264]
8.5. 7-Oxanobornadiene dicarboxylates
The Finn laboratory have described the use of 7-oxanoborna-
diene dicarboxylate (OND) frameworks as conjugation partners
for cysteine in BSA (also reporting crossreactivity with amine
groups).[265] ONDs are potent Michael acceptors, the reactivities
of which can be tailored by varying the functionalities adjacent
to the reactive double bond. OND frameworks can be func-
tionalised to a high degree, including with fluorophores, usual-
ly in three to five steps. It was found that attachment of
a dansyl moiety to the ring portion resulted in a quenching of
fluorescence and that conjugation regenerated this. As well as
this fluorogenic quality, it was also found that a retro Diels–
Alder can take place, releasing a furan moiety and a thioether
(Scheme 29). This was found to be dependent on substituents,
Scheme 28. N-terminal cysteine modification with 2-cyanobenzothiazoles.
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thus allowing release behaviour to be adjusted according to
the desired application.[266]
8.6. Photochemical alkylation
A method for rapid photoinduced dehydrative modification at
cysteine was presented by Arumugam et al. They photochemi-
cally generated a diverse range of &&3-(hydroxymethyl)naph-
thalen-2-ol OK?&& derivatives from 2-naphthoquinone-3-me-
thides, which were able to react with cysteine within BSA to
form thioether linkages under brief irradiation at 350 nm;
these linkages remained intact under ambient conditions.[267]
The reaction was found to be reversible under further irradia-
tion under dilute conditions, and it might have application in
light-directed drug delivery involving caged substrates
(Scheme 30). Similarly to the thiol-ene and -yne reactions, gen-
erality is dependent on the stability of the protein to irradia-
tion (Section 6).
8.7. Allenamides
A wide range of synthetically accessible C-substituted allena-
mide reagents were able to react with cysteine residues in
peptides and proteins.[268] These reagents showed exceptional
stabilities, with no signs of hydrolysis or polymerisation. The
reactions proceed by Michael addition, resulting in vinylsulfide
linkages (Scheme 31). Conjugates were found to be stable, and
should have application in settings in which a stable and irre-
versible bond is desired, such as for imaging purposes.
8.8. Arylpropionitriles
The Wagner lab have recently shown that 3-arylpropionitrile
reagents are suitable as selective coupling partners for cys-
teine.[269] These electron-deficient reagents, which are functio-
nalisable, undergo efficient and selective reaction with cysteine
residues. The conjugates formed were tested for stability in
serum, and were found to exhibit stabilities superior to those
of conjugates formed by maleimide–thiol coupling. The reac-
tion scope has been further developed for syntheses of hetero-
bifunctional linkers for use in therapeutic conjugations such as
in antibody–drug conjugate synthesis. Sodium 4-((4-(cyanoe-
thynyl)benzoyl)oxy)-2,3,5,6-tetrafluorobenzenesulfonate (CBTF)
was synthesised and presented as an alternative to the com-
monly used SMCC, containing an arylpropionitrile system at
one terminus for conjugation to cysteine on an antibody and
an ester linkage for amide formation with an amine-containing
moiety on the other terminus, in this case dyes for analytical
purposes (Scheme 32).[54] The conjugates were found to be
highly stable in plasma, and the methodology should find ap-
plication in drug conjugation strategies, as well as in other
fields. Indeed, a range of heterobifunctional linkers containing
arylpropionitrile groups have recently become commercially
available, including a compound containing a maleimide and
an arylpropionitrile moiety for thiol–thiol conjugation.[54]
Scheme 29. Oxanorbornadiene dicarboxylates as conjugation partners for
cysteine.
Scheme 30. Reversible photochemical modification of cysteine.
Scheme 31. Reaction between cysteine and C-substituted allenamides.
Scheme 32. Formation of antibody–dye conjugates by use of arylpropionitriles.
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9. Summary and Outlook
This review has focused on the importance of cysteine as
a tool for site-selective and specific protein modification, as ex-
emplified by numerous application-based reports, and the
emergence of new methodologies in just the last few years
alone. The introduction of cysteine into a protein is in general
much more facile and straightforward than unnatural amino
acid incorporation techniques involving manipulation of bio-
synthetic machinery. In addition, selectivity superior to that
achievable with alternative reactive endogenous amino acids
can be obtained.
Protein modification involving cysteine is more industrially
feasible, as shown by the emergence of ADCs based on cys-
teine chemistry already available on the market. As well as
single site modification, dual modifications can be achieved,
thanks to differential reactivities of varying cysteine residues
(pKa is highly dependent on environment) as well as cysteine’s
wide reactivity profile. We hypothesise that cysteine-based
chemistry will continue to expand in the years to come and, in
particular, look forward to seeing further development of these
exciting and varied methodologies in various applications.
Note added in proof : Hocek’s group demonstrated DNA–pro-
tein crosslinking between a DNA-binding portion of the
tumour suppressor protein p53, and the binding DNA itself, in
which one nucleobase was modified with a vinylsulfonamide
group for Michael addition with a cysteine. Positively, out of
two cysteine residues present in p53, only the one within the
DNA-binding region was reactive.[270] In further work, a bifunc-
tional conjugation moiety containing both an azide and a vinyl-
sulfonamide was presented as a bioconjugation reagent.[271]
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Chemical Protein Modification
through Cysteine
Cysteine residues and bioconjugation:
Chemical protein modification is used
to construct proteins with enhanced
and/or altered properties useful for
a vast range of applications. Modifica-
tion at only a single site ensures homo-
geneity, and the relatively uncommon
and uniquely reactive natural residue
cysteine allows for selective reactions
with a diverse range of coupling part-
ners.
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